Posted by Michael Wonder on 07 Oct 2017
FDA approves implantable device to treat moderate to severe central sleep apnea
6 October 2017 - The U.S. FDA today approved a new treatment option for patients who have been diagnosed with moderate to severe central sleep apnea.
The Remedē System is an implantable device that stimulates a nerve located in the chest that is responsible for sending signals to the diaphragm to stimulate breathing.
“This implantable device offers patients another treatment option for central sleep apnea,” said Tina Kiang, Ph.D., acting director of the Division of Anesthesiology, General Hospital, Respiratory, Infection Control, and Dental Devices in the FDA’s Center for Devices and Radiological Health. “Patients should speak with their health care providers about the benefits and risks of this new treatment compared to other available treatments.”
